After graduate school, I continued to study the brain's molecular changes during Alzheimer disease. I developed a PET-to-histology approach to evaluate anti-amyloid-β therapies in the first clinical trial in dominantly inherited AD (DIAN-TU-001). To quantify the level of amyloid-β deposition, tauopathy, microgliosis, and astrocytosis from hundreds of brain tissue sections, I developed a method that first used a deep-learning based method originally designed to detect cell nuclei, to derive an initial guess of where the amyloid-β and tau deposits or microglia or astrocyte cell bodies were, then derived a threshold that would separate these stained features from the background, which yielded an estimate of the stained area fraction (the amount of area these features occupied compared to the brain region overall). Using this approach, I found that while anti-amyloid-β therapies remove amyloid-β deposits, they didn't seem to alter the levels of tauopathy, microgliosis, and astrocytosis.
I also developed a method to segment the meninges from MR images. The meninges are a thin layer of tissue that wrap around the brain, which make them difficult to segment as their own structure (often they are lumped together with brain parenchyma or CSF and sometimes even skull bone). I developed a method that first used a whole-head segmentation tool as a starting point, which contains the meninges within its CSF label, then used a ratio of T1-weighted to T2-weighed MRI contrast to separate the meninges from CSF (meninges are bright on T1-weighted images and dark on T2-weighted images, while CSF is dark on T1-weighted images and bright on T2-weighted images). Segmenting the meninges is important for studying the characteristics of off-target signals of the 18F-MK-6240 tau PET radioligand, which typically localize to the meninges, but these signals can spill into the cerebral and cerebellar cortices and interfere with the quantification of tau burden.